Best Practices in the Treatment and Management of Melanoma: Expert Strategies on Evolving Combinations for Optimized Patient Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2023 to March 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Bristol Myers Squibb

Melanoma is the most serious type of skin cancer. It occurs in skins cells called melanocytes, and while it is predominantly found in the skin, it can occur in any area of the body that contains melanocytes. Melanoma will be found in approximately 106,110 people in the United States in 2022 according to the National Cancer Institute. While it is the least common amongst skin cancers, it is by far the deadliest, with 7,180 people expected to die in 2022. Both of those numbers have been rising in recent years. In the early stages of melanoma, prognosis is usually good for patients, but when the melanoma becomes metastatic and spreads to other areas of the body, prognosis is especially poor. Fortunately for patients with metastatic melanoma, and the physicians that treat them, significant progress has been made in the treatment of this deadly disease over the past few years, especially in the area of immunotherapies and novel combinations.

Upon completion of this activity, participants will be able to:

  • Discuss the clinical and economic burden of melanoma, including factors that contribute to poor prognosis and increased costs

  • Explore recent clinical data and updates regarding immunotherapy as single-agent or in combination strategies in the treatment of metastatic melanoma

  • Analyze the role of lag-3 blocking antibodies in combination with immune checkpoint inhibitors for patients with metastatic melanoma

  • Identify patients with metastatic melanoma who may benefit from combination immune checkpoint inhibitor-based treatment

  • Examine adverse events that may occur with the use of immune checkpoint inhibitor-based combinations and how they should be identified and managed for improved patient adherence and quality of life

  • Assess managed care considerations to facilitate optimal use of novel combination options, including ICI-based combinations, in metastatic melanoma


Faculty: Hussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Tawbi has served as a consultant for Bristol Myers Squib, Boxer Capital, Eisai, Genentech, Iovance, Jazz Pharmaceuticals, Karyopharm, Merck, Novartis, and Pfizer. He has received grant/research support from Bristol Myers Squib, Eisai, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and RAPT. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grant from
Bristol Myers Squibb

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue